☰

Alexander J. Muller - Publications

Affiliations: 
Biochemistry Drexel University College of Medicine, Philadelphia, PA, United States 
Area:
Pharmacology, Oncology, Molecular Biology
Tree Info Similar researchers PubMed Report error

66 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Muller AJ, Mondal A, Dey S, Prendergast GC. IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation. Frontiers in Oncology. 13: 1165298. PMID 37182174 DOI: 10.3389/fonc.2023.1165298  0.461
2023 Muller AJ, Thomas S, Prendergast GC. A Brief Overview of Cancer Vaccines. Cancer Journal (Sudbury, Mass.). 29: 34-37. PMID 36693156 DOI: 10.1097/PPO.0000000000000640  0.321
2022 Merlo LMF, Peng W, DuHadaway JB, Montgomery JD, Prendergast GC, Muller AJ, Mandik-Nayak L. The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. Journal of Immunology (Baltimore, Md. : 1950). 208: 571-581. PMID 34965962 DOI: 10.4049/jimmunol.2100705  0.304
2021 Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop LD, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. IDO1 Signaling Through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research. PMID 33622713 DOI: 10.1158/2326-6066.CIR-20-0226  0.324
2020 Merlo LMF, DuHadaway JB, Montgomery JD, Peng WD, Murray PJ, Prendergast GC, Caton AJ, Muller AJ, Mandik-Nayak L. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Frontiers in Immunology. 11: 1861. PMID 32973768 DOI: 10.3389/Fimmu.2020.01861  0.407
2020 Dey S, Sutanto-Ward E, Kopp KL, DuHadaway J, Mondal A, Ghaban D, Lecoq I, Zocca MB, Merlo LMF, Mandik-Nayak L, Andersen MH, Pedersen AW, Muller AJ. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 and CD4 T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. Journal For Immunotherapy of Cancer. 8. PMID 32690770 DOI: 10.1136/Jitc-2020-000605  0.354
2020 Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop L, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. Abstract 1474: IDO1 signaling supports inflammatory neovascularization Cancer Research. 80: 1474-1474. DOI: 10.1158/1538-7445.Am2020-1474  0.558
2019 Prendergast GC, Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Winter JM, et al. Abstract A101: IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A101  0.396
2018 Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP. Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry. 162: 455-464. PMID 30469041 DOI: 10.1016/J.Ejmech.2018.11.010  0.421
2018 Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis MT, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, et al. Host gene status influences tumor progression and radiotherapy response in -driven sporadic pancreatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30266763 DOI: 10.1158/1078-0432.Ccr-18-0814  0.441
2018 Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, Prendergast GC. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology. 8: 370. PMID 30254983 DOI: 10.3389/Fonc.2018.00370  0.459
2018 Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Seminars in Immunopathology. PMID 30203227 DOI: 10.1007/S00281-018-0702-0  0.428
2018 Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2. Journal of the American College of Surgeons. PMID 29426021 DOI: 10.1016/J.Jamcollsurg.2017.12.052  0.322
2018 Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. International Review of Cell and Molecular Biology. 336: 175-203. PMID 29413890 DOI: 10.1016/Bs.Ircmb.2017.07.004  0.525
2018 Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. Trends in Cancer. 4: 38-58. PMID 29413421 DOI: 10.1016/J.Trecan.2017.11.005  0.507
2017 Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Research. 77: 6795-6811. PMID 29247038 DOI: 10.1158/0008-5472.Can-17-2285  0.361
2017 Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, Sela DA, Muller AJ, Mullin JM, Albert K, Gilligan JP, DiGuilio K, Dilbarova R, Alexander W, Prendergast GC. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Research. PMID 28292977 DOI: 10.1158/0008-5472.Can-16-2929  0.372
2016 Mondal A, Smith C, DuHadaway JB, Sutanto-Ward E, Prendergast GC, Bravo-Nuevo A, Muller AJ. IDO1 is an Integral Mediator of Inflammatory Neovascularization. Ebiomedicine. PMID 27889479 DOI: 10.1016/J.Ebiom.2016.11.013  0.565
2016 Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L. IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. Journal of Immunology (Baltimore, Md. : 1950). PMID 27183624 DOI: 10.4049/Jimmunol.1600141  0.344
2015 Malachowski WP, Winters M, DuHadaway JB, Lewis-Ballester A, Badir S, Wai J, Rahman M, Sheikh E, LaLonde JM, Yeh SR, Prendergast GC, Muller AJ. O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. European Journal of Medicinal Chemistry. 108: 564-576. PMID 26717206 DOI: 10.1016/J.Ejmech.2015.12.028  0.338
2015 Mondal A, DuHadaway JB, Sutanto-Ward E, Smith C, Prendergast GC, Bravo-Nuevo A, Muller AJ. Abstract 5223: A novel pro-angiogenic role for IDO1 in inflammatory tumor promotion Cancer Research. 75: 5223-5223. DOI: 10.1158/1538-7445.Am2015-5223  0.592
2014 Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. IDO2 in Immunomodulation and Autoimmune Disease. Frontiers in Immunology. 5: 585. PMID 25477879 DOI: 10.3389/Fimmu.2014.00585  0.41
2014 Pigott E, DuHadaway JB, Muller AJ, Gilmour S, Prendergast GC, Mandik-Nayak L. 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity. 47: 409-18. PMID 24798341 DOI: 10.3109/08916934.2014.914507  0.316
2014 Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy : Cii. 63: 721-35. PMID 24711084 DOI: 10.1007/S00262-014-1549-4  0.562
2014 Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. International Immunology. 26: 357-67. PMID 24402311 DOI: 10.1093/Intimm/Dxt073  0.433
2014 Muller AJ, Smith C, Chang MY, DuHadaway J, Mondal A, Flick H, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC. Abstract 3665: IDO1 is an integrative determinant of tumor-promoting, pathogenic inflammation Cancer Research. 74: 3665-3665. DOI: 10.1158/1538-7445.Am2014-3665  0.751
2013 Flick HE, Lalonde JM, Malachowski WP, Muller AJ. The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1. International Journal of Tryptophan Research : Ijtr. 6: 35-45. PMID 24023520 DOI: 10.4137/IJTR.S12094  0.715
2012 Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discovery. 2: 722-35. PMID 22822050 DOI: 10.1158/2159-8290.Cd-12-0014  0.742
2012 Smith C, Chang M, Flick H, DuHadaway J, Mandik-Nayak L, Laury-Kleintop L, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. Abstract 295: IDO drives tumor-promoting, pathogenic inflammation in lung Cancer Research. 72: 295-295. DOI: 10.1158/1538-7445.Am2012-295  0.748
2011 Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, Prendergast GC. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biology & Therapy. 12: 1050-8. PMID 22157149 DOI: 10.4161/cbt.12.12.18142  0.332
2011 Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Current Medicinal Chemistry. 18: 2257-62. PMID 21517753 DOI: 10.2174/092986711795656072  0.41
2010 Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunology, Immunotherapy : Cii. 59: 1655-63. PMID 20640572 DOI: 10.1007/S00262-010-0891-4  0.528
2010 Muller AJ, Mandik-Nayak L, Prendergast GC. Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy. 2: 293-7. PMID 20635895 DOI: 10.2217/Imt.10.22  0.445
2010 Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, Prendergast GC. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Molecular Cancer Therapeutics. 9: 1864-71. PMID 20530717 DOI: 10.1158/1535-7163.Mct-10-0185  0.491
2010 Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. The American Journal of Pathology. 176: 2082-7. PMID 20228228 DOI: 10.2353/Ajpath.2010.091173  0.444
2010 Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Research. 70: 1845-53. PMID 20160032 DOI: 10.1158/0008-5472.Can-09-3613  0.543
2010 Muller AJ, DuHadaway JB, Chang MY, Soler AP, Prendergast GC. Abstract 1347: Immune escape mediator IDO is a crucial defining element of ‘cancer-associated’ inflammation in the tumor microenvironment Cancer Research. 70: 1347-1347. DOI: 10.1158/1538-7445.Am10-1347  0.517
2009 Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 182: 7509-17. PMID 19494274 DOI: 10.4049/Jimmunol.0804328  0.382
2009 Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. Journal of the American College of Surgeons. 208: 781-7; discussion 78. PMID 19476837 DOI: 10.1016/J.Jamcollsurg.2008.12.018  0.397
2009 Prendergast GC, Metz R, Muller AJ. IDO recruits Tregs in melanoma. Cell Cycle (Georgetown, Tex.). 8: 1818-9. PMID 19471123 DOI: 10.4161/Cc.8.12.8887  0.323
2009 Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochimica Et Biophysica Acta. 1795: 25-36. PMID 18930786 DOI: 10.1016/J.Bbcan.2008.09.001  0.373
2008 Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the National Academy of Sciences of the United States of America. 105: 17073-8. PMID 18952840 DOI: 10.1073/Pnas.0806173105  0.473
2008 Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase Journal of Medicinal Chemistry. 51: 4968-4977. PMID 18665584 DOI: 10.1021/Jm800512Z  0.372
2008 Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunological Reviews. 222: 206-21. PMID 18364004 DOI: 10.1111/J.1600-065X.2008.00610.X  0.528
2008 Ramalingam A, Duhadaway JB, Sutanto-Ward E, Wang Y, Dinchuk J, Huang M, Donover PS, Boulden J, McNally LM, Soler AP, Muller AJ, Duncan MK, Prendergast GC. Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Research. 68: 1683-90. PMID 18339847 DOI: 10.1158/0008-5472.Can-07-6072  0.341
2008 Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. Journal of Medicinal Chemistry. 51: 1706-18. PMID 18318466 DOI: 10.1021/Jm7014155  0.428
2008 Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene. 27: 2851-7. PMID 18026137 DOI: 10.1038/Sj.Onc.1210939  0.53
2007 Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Research. 67: 7605-12. PMID 17699764 DOI: 10.1158/0008-5472.Can-07-1100  0.407
2007 Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Research. 67: 7082-7. PMID 17671174 DOI: 10.1158/0008-5472.Can-07-1872  0.463
2007 Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Current Cancer Drug Targets. 7: 31-40. PMID 17305476 DOI: 10.2174/156800907780006896  0.554
2007 Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Research. 67: 792-801. PMID 17234791 DOI: 10.1158/0008-5472.Can-06-2925  0.442
2007 Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Research. 67: 100-7. PMID 17210688 DOI: 10.1158/0008-5472.Can-06-2742  0.478
2007 Muller AJ, Metz R, Prendergast GC. Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan International Congress Series. 1304: 250-261. DOI: 10.1016/j.ics.2007.07.042  0.406
2007 Muller AJ, Prendergast GC. Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition Cancer Immunotherapy. 347-368. DOI: 10.1016/B978-012372551-6/50083-3  0.391
2006 Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nature Reviews. Cancer. 6: 613-25. PMID 16862192 DOI: 10.1038/Nrc1929  0.455
2006 Gaspari P, Banerjee T, Malachowski WP, Muller AJ, Prendergast GC, DuHadaway J, Bennett S, Donovan AM. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. Journal of Medicinal Chemistry. 49: 684-92. PMID 16420054 DOI: 10.1021/Jm0508888  0.327
2005 Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Research. 65: 8065-8. PMID 16166276 DOI: 10.1158/0008-5472.Can-05-2213  0.431
2005 Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opinion On Therapeutic Targets. 9: 831-49. PMID 16083346 DOI: 10.1517/14728222.9.4.831  0.453
2005 Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine. 11: 312-9. PMID 15711557 DOI: 10.1038/Nm1196  0.521
2005 Malachowski WP, Metz R, Prendergast GC, Muller AJ. A new cancer immunosuppression target: Indoleamine 2,3-dioxygenase (IDO). A review of the IDO mechanism, inhibition and therapeutic applications Drugs of the Future. 30: 897-909. DOI: 10.1358/Dof.2005.030.09.918200  0.482
2005 Muller AJ, DuHadaway JB, Sutanto-Ward E, Donover PS, Prendergast GC. Pharmacological Inhibition of the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO) Cooperatively Leverages Cytotoxic Chemotherapy Journal of Immunotherapy. 28: 650. DOI: 10.1097/01.Cji.0000191073.49748.5A  0.321
2004 Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biology & Therapy. 3: 1236-42. PMID 15611650 DOI: 10.4161/Cbt.3.12.1232  0.382
2004 Muller A, DuHadaway J, Sutanto-Ward E, Donover P, Prendergast G. 101 Combinatorial cancer therapy using a pharmacological inhibitor of indoleamine 2,3-dioxygenase (IDO), a target of the cancer suppression gene Bin1 European Journal of Cancer Supplements. 2: 33. DOI: 10.1016/S1359-6349(04)80109-5  0.335
2003 DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene. 22: 3578-88. PMID 12789266 DOI: 10.1038/Sj.Onc.1206481  0.37
2000 Muller AJ, Teresky AK, Levine AJ. A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13. Proceedings of the National Academy of Sciences of the United States of America. 97: 8421-6. PMID 10890890 DOI: 10.1073/Pnas.140208197  0.307
1999 Muller AJ, Heiden KB, Teresky AK, Levine AJ. Genetic mapping of the embryonal carcinoma transplantation resistance locus Gt(B6) to mouse Chromosome 8. Immunogenetics. 49: 949-56. PMID 10501837 DOI: 10.1007/S002510050578  0.33
Show low-probability matches.